73 related articles for article (PubMed ID: 31843982)
1. A Runaway PRH/HHEX-Notch3-Positive Feedback Loop Drives Cholangiocarcinoma and Determines Response to CDK4/6 Inhibition.
Kitchen P; Lee KY; Clark D; Lau N; Lertsuwan J; Sawasdichai A; Satayavivad J; Oltean S; Afford S; Gaston K; Jayaraman PS
Cancer Res; 2020 Feb; 80(4):757-770. PubMed ID: 31843982
[TBL] [Abstract][Full Text] [Related]
2. YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/β-catenin axis.
Shi X; Hu Z; Bai S; Zong C; Xue H; Li Y; Li F; Chen L; Xuan J; Xia Y; Wei L; Shen F; Wang K
J Gene Med; 2024 May; 26(5):e3689. PubMed ID: 38676365
[TBL] [Abstract][Full Text] [Related]
3. Cholangiocarcinoma: molecular pathways and therapeutic opportunities.
I Ilyas S; Borad MJ; Patel T; Gores GJ
Semin Liver Dis; 2014 Nov; 34(4):456-64. PubMed ID: 25369307
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs.
Sanchon-Sanchez P; Briz O; Macias RIR; Abad M; Sanchez-Martin A; Marin JJG; Lozano E
Biomed Pharmacother; 2023 Dec; 168():115658. PubMed ID: 37832404
[TBL] [Abstract][Full Text] [Related]
5. The inhibition of β-catenin activity by luteolin isolated from Paulownia flowers leads to growth arrest and apoptosis in cholangiocarcinoma.
Yang H; Zhao Y; Song W; Fan G
Int J Biol Macromol; 2024 Jan; 254(Pt 1):127627. PubMed ID: 37884243
[TBL] [Abstract][Full Text] [Related]
6. Cholangiocarcinoma: novel therapeutic targets.
Sato K; Glaser S; Alvaro D; Meng F; Francis H; Alpini G
Expert Opin Ther Targets; 2020 Apr; 24(4):345-357. PubMed ID: 32077341
[No Abstract] [Full Text] [Related]
7. The histone lysine acetyltransferase KAT2B inhibits cholangiocarcinoma growth: evidence for interaction with SP1 to regulate NF2-YAP signaling.
Ma W; Zhang J; Chen W; Liu N; Wu T
J Exp Clin Cancer Res; 2024 Apr; 43(1):117. PubMed ID: 38641672
[TBL] [Abstract][Full Text] [Related]
8. RBM10 C761Y mutation induced oncogenic ASPM isoforms and regulated β-catenin signaling in cholangiocarcinoma.
Chang J; Zhang Y; Zhou T; Qiao Q; Shan J; Chen Y; Jiang W; Wang Y; Liu S; Wang Y; Yu Y; Li C; Li X
J Exp Clin Cancer Res; 2024 Apr; 43(1):104. PubMed ID: 38576051
[TBL] [Abstract][Full Text] [Related]
9. Molecular profiling reveals potential targets in cholangiocarcinoma.
Liu D; Shi Y; Chen H; Nisar MA; Jabara N; Langwinski N; Mattson S; Nagaoka K; Bai X; Lu S; Huang CK
World J Gastroenterol; 2023 Jul; 29(25):4053-4071. PubMed ID: 37476584
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evidence for preventive and curative effects of resveratrol on xenograft cholangiocarcinogenesis.
Thongchot S; Ferraresi A; Vidoni C; Salwa A; Vallino L; Kittirat Y; Loilome W; Namwat N; Isidoro C
Cancer Lett; 2024 Feb; 582():216589. PubMed ID: 38097133
[TBL] [Abstract][Full Text] [Related]
11. Babaodan overcomes cisplatin resistance in cholangiocarcinoma via inhibiting YAP1.
Li J; Ma X; Xu F; Yan Y; Chen W
Pharm Biol; 2024 Dec; 62(1):314-325. PubMed ID: 38571483
[TBL] [Abstract][Full Text] [Related]
12. FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma.
Zhen Y; Liu K; Shi L; Shah S; Xu Q; Ellis H; Balasooriya ER; Kreuzer J; Morris R; Baldwin AS; Juric D; Haas W; Bardeesy N
Nat Commun; 2024 May; 15(1):3805. PubMed ID: 38714664
[TBL] [Abstract][Full Text] [Related]
13. Copper Increases the Sensitivity of Cholangiocarcinoma Cells to Tripterine by Inhibiting TMX2-Mediated Unfolded Protein Reaction Activation.
Liu H; Xu L; Zhang Y; Xie Y; Wang L; Zhou Y; Wang Z; Pan Y; Li W; Xu L; Xu X; Wang T; Meng K; He J; Qiu Y; Xu G; Ge W; Zhu Y; Wang L
Adv Healthc Mater; 2023 Oct; 12(26):e2300913. PubMed ID: 37119498
[TBL] [Abstract][Full Text] [Related]
14. Notch3 drives development and progression of cholangiocarcinoma.
Guest RV; Boulter L; Dwyer BJ; Kendall TJ; Man TY; Minnis-Lyons SE; Lu WY; Robson AJ; Gonzalez SF; Raven A; Wojtacha D; Morton JP; Komuta M; Roskams T; Wigmore SJ; Sansom OJ; Forbes SJ
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12250-12255. PubMed ID: 27791012
[TBL] [Abstract][Full Text] [Related]
15. HHEX suppresses advanced thyroid cancer by interacting with TLE3.
Xu Z; Feng Y; Yan Y; Jin H; Chen Y; Han Y; Huang S; Feng F; Fu H; Yin Y; Huang Y; Wang H; Cheng W
Mol Cell Endocrinol; 2023 Aug; 574():111988. PubMed ID: 37302518
[TBL] [Abstract][Full Text] [Related]
16. In Vivo Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma.
Younger NT; Wilson ML; Martinez Lyons A; Jarman EJ; Meynert AM; Grimes GR; Gournopanos K; Waddell SH; Tennant PA; Wilson DH; Guest RV; Wigmore SJ; Acosta JC; Kendall TJ; Taylor MS; Sproul D; Mill P; Boulter L
Cancer Res; 2022 Apr; 82(8):1548-1559. PubMed ID: 35074757
[TBL] [Abstract][Full Text] [Related]
17. The cholangiocyte primary cilium in health and disease.
Mansini AP; Peixoto E; Thelen KM; Gaspari C; Jin S; Gradilone SA
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1245-1253. PubMed ID: 28625917
[TBL] [Abstract][Full Text] [Related]
18. Cholangiocarcinoma 2020: the next horizon in mechanisms and management.
Banales JM; Marin JJG; Lamarca A; Rodrigues PM; Khan SA; Roberts LR; Cardinale V; Carpino G; Andersen JB; Braconi C; Calvisi DF; Perugorria MJ; Fabris L; Boulter L; Macias RIR; Gaudio E; Alvaro D; Gradilone SA; Strazzabosco M; Marzioni M; Coulouarn C; Fouassier L; Raggi C; Invernizzi P; Mertens JC; Moncsek A; Rizvi S; Heimbach J; Koerkamp BG; Bruix J; Forner A; Bridgewater J; Valle JW; Gores GJ
Nat Rev Gastroenterol Hepatol; 2020 Sep; 17(9):557-588. PubMed ID: 32606456
[TBL] [Abstract][Full Text] [Related]
19. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Abou-Alfa GK; Sahai V; Hollebecque A; Vaccaro G; Melisi D; Al-Rajabi R; Paulson AS; Borad MJ; Gallinson D; Murphy AG; Oh DY; Dotan E; Catenacci DV; Van Cutsem E; Ji T; Lihou CF; Zhen H; Féliz L; Vogel A
Lancet Oncol; 2020 May; 21(5):671-684. PubMed ID: 32203698
[TBL] [Abstract][Full Text] [Related]
20. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Abou-Alfa GK; Macarulla T; Javle MM; Kelley RK; Lubner SJ; Adeva J; Cleary JM; Catenacci DV; Borad MJ; Bridgewater J; Harris WP; Murphy AG; Oh DY; Whisenant J; Lowery MA; Goyal L; Shroff RT; El-Khoueiry AB; Fan B; Wu B; Chamberlain CX; Jiang L; Gliser C; Pandya SS; Valle JW; Zhu AX
Lancet Oncol; 2020 Jun; 21(6):796-807. PubMed ID: 32416072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
